A New Pill Could Reduce the Risk of Having a Second Stroke

The U.S. Food and Drug Administration (FDA) recently approved a new medication called Asundexian, marketed as Sunharbo, which can help reduce the risk of strokes in specific populations. Asundexian is a daily pill designed to target a unique factor in the blood-clotting process that contributes to stroke. Research conducted by Bayer revealed that when combined with an antiplatelet therapy like aspirin, Asundexian reduced the likelihood of a second stroke by 26% over the course of a year, compared to those who received a placebo and antiplatelet therapy.

Asundexian is specifically recommended for individuals who have recently experienced an ischemic stroke, which occurs when clots obstruct blood flow to the brain, or a transient ischemic attack caused by a temporary blockage of blood flow to the brain that doesn't result in permanent damage. Dr. Ashkan Shoamanesh, a McMaster University professor of medicine and co-leader of the trial, expressed enthusiasm about the robust data and positive feedback from the international stroke community.

Strokes are categorized into two types: ischemic strokes, caused by blood vessel blockages, and hemorrhagic strokes, resulting from damaged blood vessels that rupture and cause excessive bleeding. Approximately 87% of strokes in the U.S. are ischemic. Recurrent strokes pose a significant treatment challenge, with nearly one in four occurring in people who have previously had a stroke.

Asundexian's effectiveness was evident without any notable increase in bleeding events, as reported by Bayer's data. The 26% reduction in stroke risk was achieved without compromising patient safety. Dr. Christoph Koenen, Bayer's chief medical officer, explained that the drug works by preventing small clots from growing larger and obstructing blood flow.

One of the most impressive findings was that Asundexian benefited all patients, regardless of age, geographical location, medical history, or the type of ischemic stroke they experienced. This consistency across diverse populations has generated considerable excitement among researchers. Koenen stated that Bayer is currently investigating potential additional benefits of Asundexian for various patient groups.

Studies tracking some participants for several more years demonstrated that those taking Asundexian continued to exhibit a lower risk of stroke compared to those taking a placebo. This suggests that the drug's positive effects may be long-lasting, potentially making it a lifelong treatment option. Asundexian is set to be available starting in November, and Shoamanesh anticipates that patients will need to take the daily pills for the remainder of their lives to fully benefit from the treatment.

According to the data, the drug's advantages appear to persist even over extended periods, positioning it as the new standard of care for recurrent stroke prevention.